Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Hepatology

• Publication date

  2006-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/hep.21429PMID 17133473
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis.

  2006cited by this paper
• Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C

  2006cited by this paper
• Hepatic steatosis and insulin resistance: does etiology make a difference?

  2006cited by this paper
• Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection

  2006cited by this paper
• Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data.

  2006cited by this paper
• Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease.

  2005cited by this paper
• Steatosis: Co‐factor in other liver diseases

  2005cited by this paper
• Metabolic syndrome.

  2005cited by this paper
• An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation.

  2005cited by this paper
• Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity.

  2005cited by this paper
• Insulin resistance: A metabolic pathway to chronic liver disease

  2005cited by this paper
• Impact of steatosis on progression of fibrosis in patients with mild hepatitis C

  2005cited by this paper
• Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease.

  2004cited by this paper
• Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver

  2004cited by this paper
• Steatosis affects chronic hepatitis C progression in a genotype specific way

  2004cited by this paper
• Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance.

  2004cited by this paper
• The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients.

  2004cited by this paper
• Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3.

  2004cited by this paper
• Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens.

  2004cited by this paper
• Liver Damage in Severely Obese Patients: a Clinical-Biochemical-Morphologic Study on 1,000 Liver Biopsies

  2004cited by this paper
• Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver

  2004cited by this paper
• Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies

  2003cited by this paper
• Impaired IRS‐1/PI3‐kinase signaling in patients with HCV: A mechanism for increased prevalence of type 2 diabetes

  2003cited by this paper
• The metabolic syndrome.

  2003cited by this paper
• Hepatitis C virus–associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis

  2003cited by this paper
• Hepatitis C virus and liver steatosis: Is it the virus? Yes it is, but not always

  2002cited by this paper
• Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients.

  2002cited by this paper
• Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response

  2002cited by this paper
• High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: A potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis

  2001cited by this paper
• Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

  2001cited by this paper
• Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C.

  2001cited by this paper
• Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon.

  2001cited by this paper
• Expression of liver steatosis in hepatitis C virus infection and pattern of response to α-interferon

  2001cited by this paper
• Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.

  2000cited by this paper
• Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis

  1999cited by this paper
• Insulin and insulin‐like growth factor‐1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: Differential effects on signal transduction pathways

  1999cited by this paper
• Steatosis and intrahepatic hepatitis C virus in chronic hepatitis

  1999cited by this paper
• Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions

  1999cited by this paper
• Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation

  1998cited by this paper
• Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets.

  1997cited by this paper
• Hepatitis C virus core protein induces hepatic steatosis in transgenic mice.

  1997cited by this paper
• Histopathological aspects of viral hepatitis

  1996cited by this paper
• Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man

  1985cited by this paper

• Metabolic Dysfunction - Associated Fatty Liver Disease (MAFLD), and Lipid-Based Insulin Resistance Markers in Hepatitis C Virus Infection (HCV)

  2026cites this paper
• Cardiometabolic Comorbidities in Patients With Chronic Hepatitis B and Impact on Incidence of Liver Complications. A Danish Nationwide Cohort Study

  2025cites this paper
• Insulin increases type I collagen synthesis in hepatic stellate cells via α5β1 integrin

  2024cites this paper
• Oleuropein as a Therapeutic Agent for Non-alcoholic Fatty Liver Disease During Hepatitis C

  2023cites this paper
• PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets.

  2023cites this paper
• A pharmaceutical formulation containing Cecropia pachystachya alleviates metabolic alterations in a hypercaloric diet obesity model in Swiss mice

  2022cites this paper
• The Change in Metabolic Syndrome Status and the Risk of Nonviral Liver Cirrhosis

  2021cites this paper
• Metabolic complications of hepatitis C virus infection

  2021cites this paper
• Infections at the nexus of metabolic-associated fatty liver disease

  2021cites this paper
• Higher dietary insulinaemic potential is associated with increased risk of liver steatosis and fibrosis

  2021cites this paper
• Diagnostic and prognostic significance of hepatic steatosis in patients with chronic hepatitis C

  2021cites this paper
• Changing clinical management of NAFLD in Asia

  2021cites this paper
• Association of Adiponutrin/Patatin Like Phospholipase 3 (PNPLA3) I148M Gene Variant with Chronic Hepatitis C in Egyptian Children

  2021cites this paper
• Clinical parallels and experience of antivira l therapy in chronic hepatitis with polycystic ovary syndrome

  2020cites this paper
• Obstructive Sleep Apnea and Non-alcoholic Fatty Liver Disease in Obese Patients Undergoing Bariatric Surgery

  2020cites this paper
• Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

  2020cites this paper
• Hepatitis C virus genotypes and associated risk factors in the state of Pará, Northern Brazil

  2020cites this paper
• Клинические параллели и опыт противовирусной терапии при хроническом гепатите с синдромом поликистозных яичников

  2020cites this paper
• Evaluation of extra-hepatic risk factors for severe liver disease

  2019cites this paper
• Review article: iron disturbances in chronic liver diseases other than haemochromatosis – pathogenic, prognostic, and therapeutic implications

  2019cites this paper
• Serum cytokines, adipokines and ferritin for non-invasive assessment of liver fibrosis in chronic liver disease: a systematic review

  2019cites this paper
• HOMA‐IR: An independent predictor of advanced liver fibrosis in nondiabetic non‐alcoholic fatty liver disease

  2019cites this paper
• Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

  2019cites this paper
• A Novel Automatic Digital Algorithm that Accurately Quantifies Steatosis in NAFLD on Histopathological Whole‐Slide Images

  2019cites this paper
• Non‐Alcoholic Fatty Liver Disease

  2018cites this paper
• The Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 2: Management and special groups

  2018cites this paper
• Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct‐acting antiviral agents

  2018cites this paper
• Non-alcoholic fatty liver disease and obesity: the role of the gut bacteria

  2018cites this paper
• Non-alcoholic Fatty Liver Disease in Morbidly Obese Individuals Undergoing Bariatric Surgery: Prevalence and Effect of the Pre-Bariatric Very Low Calorie Diet

  2018cites this paper
• Elbasvir/Grazoprevir and Sofosbuvir for HCV Genotype 3 Infection With Compensated Cirrhosis: A Randomized Trial

  2018cites this paper
• Une étude des effets des monomères cycliques d'acides gras issus d'une huile végétale chauffée sur les marqueurs de la stéatose hépatique, de l'inflammation et du stress oxydant chez le rat

  2018cites this paper
• Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial

  2018cites this paper
• MicroRNA‐206 prevents the pathogenesis of hepatocellular carcinoma by modulating expression of met proto‐oncogene and cyclin‐dependent kinase 6 in mice

  2017cites this paper
• Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease

  2017cites this paper
• Variant is Associated with Liver Damage in Patients with Non-alcoholic Fatty Liver Disease

  2017cites this paper
• Mortality associated with gastrointestinal bleeding in children: A retrospective cohort study

  2017cites this paper
• Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review

  2017cites this paper
•  The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.

  2016cites this paper
• Is there an influence of hepatic steatosis on fibrosis and necroinflammation in young patients with chronic viral hepatitis B?

  2016cites this paper
• Mechanisms of intrahepatic triglyceride accumulation.

  2016cites this paper
• A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients: multicentric study

  2016cites this paper
• Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality?

  2016cites this paper
• Diabetes Mellitus Increases Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Virus Patients: A Systematic Review

  2016cites this paper
• Association of patatin-like phospholipase domain-containing protein 3 gene polymorphisms with susceptibility of nonalcoholic fatty liver disease in a Han Chinese population

  2016cites this paper
• Relationship between non-alcoholic fatty liver disease, metabolic syndrome and insulin resistance in Korean adults: A cross-sectional study.

  2016cites this paper
• Metabolic alterations and hepatitis C: From bench to bedside.

  2016cites this paper
• MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease.

  2016cites this paper
• Insulin Resistance is Associated With Significant Liver Fibrosis in Chronic Hepatitis C Patients: A Systemic Review and Meta-Analysis

  2016cites this paper
• The Role of Bacterial Products and Intestinal Microbiota in Non-Alcoholic Fatty Liver Disease

  2015cites this paper
• Hepatitis C virus infection: Are there still specific problems with genotype 3?

  2015cites this paper
• Effects of cumin on nonalcoholic steatohepatitis: A double blind, randomised, controlled trial

  2015influential citation
• Elevated whole blood viscosity is associated with insulin resistance and non‐alcoholic fatty liver

  2015cites this paper
• Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis

  2015cites this paper
• Insulin resistance, non-alcoholic fatty liver disease and hepatitis C virus infection.

  2015cites this paper
• Diabetic foot syndrome: Immune-inflammatory features as possible cardiovascular markers in diabetes.

  2015cites this paper
• Experience of Using Metformin in Patients Infected with HCV Genotype 3 with Concomitant Metabolic Disorders

  2015cites this paper
• The Global Nonalcoholic Fatty Liver Disease Epidemic: What a Radiologist Needs to Know

  2015cites this paper
• Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma

  2015cites this paper
• DMM019950 1037..1046

  2015cites this paper
• Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases.

  2014cites this paper
• The impact of obesity and metabolic syndrome on chronic hepatitis C.

  2014cites this paper
• Update : Hepatitis C Facts and fictions of HCV and comorbidities : Steatosis , diabetes mellitus , and cardiovascular diseases

  2014cites this paper
• Clinical approaches to non-alcoholic fatty liver disease.

  2014cites this paper
• Concepts and Treatment Approaches in Nonalcoholic Fatty Liver Disease

  2014cites this paper
• Insulin resistance and metabolic syndrome are related to non-alcoholic fatty liver disease, but not visceral adiposity index, in severely obese patients.

  2014cites this paper
• Increased soluble CD36 is linked to advanced steatosis in nonalcoholic fatty liver disease

  2014cites this paper
• Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease

  2014cites this paper
• Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis.

  2014cites this paper
• Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C.

  2013cites this paper
• Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target.

  2013cites this paper
• The Hep573 Study: a randomised, double-blind, placebo-controlled clinical trial of silymarin alone, and silymarin combined with antioxidants in chronic hepatitis C | NOVA. The University of Newcastle's Digital Repository

  2013cites this paper
• Sexually Dimorphic Genome-Wide Binding of Retinoid X Receptor alpha (RXRα) Determines Male-Female Differences in the Expression of Hepatic Lipid Processing Genes in Mice

  2013cites this paper
• Avaliação da resistência à insulina em pacientes com hepatite C crônica não diabéticos

  2013cites this paper
• On the assessment and impact of liver fibrosis in patients with chronic hepatitis C

  2013cites this paper
• Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes.

  2013cites this paper
• Prevalence of insulin resistance in chronic hepatitis C genotype 1 and 3 patients.

  2013cites this paper
• IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease.

  2012cites this paper
• Inflammation and fibrogenesis in steatohepatitis

  2012cites this paper
• Lipids and HCV

  2012cites this paper
• Hepatic expression and serum levels of syndecan 1 (CD138) in patients with nonalcoholic fatty liver disease

  2012cites this paper
• THE RELATIONSHIP BETWEEN NONALCOHOLIC FATTY LIVER DISEASE AND THE METABOLIC SYNDROME

  2012cites this paper
• Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside

  2012influential citation
• Visceral adiposity index is associated with significant fibrosis in patients with non‐alcoholic fatty liver disease

  2012cites this paper
• Steatosis and insulin resistance in response to treatment of chronic hepatitis C

  2012cites this paper
• Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C.

  2012cites this paper
• Type 2 diabetes mellitus and chronic hepatitis C: which is worse? Results of a long-term retrospective cohort study.

  2012cites this paper
• Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

  2012cites this paper
• Non-alcoholic fatty liver disease: risk factors and relationship with the metabolic syndrome

  2012cites this paper
• Traitement des données manquantes en épidémiologie : application de l’imputation multiple à des données de surveillance et d’enquêtes

  2012cites this paper
• The interaction of metabolic factors with HCV infection: does it matter?

  2012cites this paper
• Insulin Resistance in Liver Diseases

  2011cites this paper
• The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis

  2011cites this paper
• [Chronic hepatitis C, steatosis and insulin resistance--clinical implications].

  2011cites this paper
• Synthesis of carboxymethylated and quaternized chitosans and their therapeutic effect on nonalcoholic Fatty liver disease.

  2011cites this paper
• Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non‐alcoholic fatty liver disease patients

  2011cites this paper
• Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection

  2011cites this paper
• High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis.

  2011cites this paper
• Current understanding of insulin resistance in hepatitis C

  2011cites this paper
• Mechanisms of hepatitis C virus-related insulin resistance.

  2011cites this paper
• Patatin‐Like phospholipase domain‐containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C

  2011cites this paper